Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GLPG3970

Small molecule · developed by Lakefront Biotherapeutics NV

Phase 2 Most advanced trial (none active)
LKFT Developer
4 Registered trials

What is GLPG3970?

GLPG3970 is an investigational oral drug studied in healthy volunteers and in patients with psoriasis, systemic lupus erythematosus and primary Sjögren syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology, Immunology
Developer
Lakefront Biotherapeutics NV (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
UA6B2TI4MO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04700280 Phase 2 Primary Sjögren Syndrome Terminated LKFT
NCT04907149 Phase 1 Healthy Completed LKFT
NCT04700267 Phase 1 Systemic Lupus Erythematosus Terminated LKFT
NCT04106297 Phase 1 Healthy Completed LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyPrimary Sjögren SyndromePsoriasisSystemic Lupus Erythematosus

More from Lakefront Biotherapeutics NV

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind GLPG3970

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.